当前位置: 首页 > 期刊 > 《中国实用医药》 > 2010年第5期
编号:11939323
端粒酶抑制剂研究进展(4)
http://www.100md.com 2010年2月15日 左利娟 李洪雪
第1页

    参见附件(3071KB,4页)。

     [32] Shay J W,Keith W N.Targeting telomerase for cancer therapeutics.Br J Cancer,2008,98:677683.

    [33] Hochreiter A E.Telomerase template antagonist GRN163L Disrupts telomere maintenance,tumor growth,and metastasis of breast cancer.Clin.Cancer Res,2006,12:31843192.

    [34] De Cian A,Lacroix L,Douarre C,TemimeSmaali N,Trentesaux C,Riou J F.Mergny,J.L.Targeting telomeres and telomerase.Biochimie,2008,90:13155.

    [35] 殷菲.以G四联体为靶点的小分子端粒酶抑制剂研究进展.化学通报,2004:271277.

    [36] Ma D L,Che C M,Yan,S C.Platinum(II)Complexes with Dipyridophenazine Ligands as Human Telomerase Inhibitors and Luminescent Probes for GQuadruplex DNA.J.AM.CHEM.SOC,2009,131:18351846.

    [37] Filaci,G.Frequency of telomerasespecific CD8+ T lymphocytes in cancer patients.blood,2005,107:15051512.

    [38] 张静,刘照旭,杨金玲.BIBR1532对p53和pRb功能缺陷的肿瘤细胞生长抑制作用的研究.山东大学学报(医学版),2006,44:11131120.

    [39] Marrone A,Sokhal P.Functional characterization of novel telomerase RNA(TERC)mutations in patients with diverse clinical and pathological presentations.Haematologica,2007,92:10131020.

    [40] Gandellini P,Folini M.Downregulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment.Biochem.Pharmacol,2007,73:17031714.

您现在查看是摘要介绍页,详见PDF附件(3071KB,4页)